---
title: Randomized Adaptive Platform Trial of Pathogen-Directed Anti-inflammatory Therapy in Severe Community-Acquired Pneumonia(Core Protocal)
nct_id: NCT07152587
overall_status: NOT_YET_RECRUITING
phase: PHASE2, PHASE3
sponsor: Qingyuan Zhan
study_type: INTERVENTIONAL
primary_condition: Severe Community-acquired Pneumonia (sCAP)
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07152587.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07152587"
ct_last_update_post_date: 2025-09-03
last_seen_at: "2026-05-12T06:38:39.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Randomized Adaptive Platform Trial of Pathogen-Directed Anti-inflammatory Therapy in Severe Community-Acquired Pneumonia(Core Protocal)

**Official Title:** Randomized, Embedded, Multifactorial, Adaptive Platform Trial of Pathogen-Directed Precision Anti-inflammatory Therapy in Severe Community-Acquired Pneumonia(Core Protocal)

**NCT ID:** [NCT07152587](https://clinicaltrials.gov/study/NCT07152587)

## Key Facts

- **Status:** NOT_YET_RECRUITING
- **Phase:** PHASE2, PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 1500
- **Lead Sponsor:** Qingyuan Zhan
- **Conditions:** Severe Community-acquired Pneumonia (sCAP)
- **Start Date:** 2025-09-08
- **Completion Date:** 2035-12-31
- **CT.gov Last Update:** 2025-09-03

## Brief Summary

Severe community-acquired pneumonia (sCAP) has a high mortality rate of 25-50%. Excessive host inflammatory responses contribute to poor outcomes. Corticosteroid therapy may provide benefit; however, the optimal dosage remains unclear, and it is uncertain whether all etiologies (e.g., Pneumocystis jirovecii, adenovirus, influenza) of sCAP can benefit equally.

This study will first establish a comprehensive trial platform based on a prospective sCAP cohort, embedding a randomized, multifactorial, adaptive platform trial (APT). The response-adaptive design will increase the likelihood of patients being assigned to more effective treatment arms, while Bayesian statistical modeling will dynamically assess the efficacy of interventions, allowing early achievement of study endpoints.

At the starting stage, two pathogen-specific APTs will be conducted, focusing on adenovirus- and pneumocystis Jirovecii-induced sCAP. Patients admitted to the ICU with confirmed diagnoses of adenovirus or pneumocystis Jirovecii-associated sCAP will be randomized into a control group or one of two corticosteroid dosage groups. The primary endpoint will be 28-day all-cause mortality. Completion of these APTs will provide a theoretical basis for novel anti-inflammatory strategies in sCAP.

Moreover, this platform will serve as an essential research infrastructure for the efficient evaluation of new therapeutic options in the event of emerging or re-emerging respiratory pathogens causing sCAP in the future.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Admission to ICU;

  * Age ≥ 18 years;

    * ICU length of stay ≤ 48 hours; ④ Meeting the IDSA/ATS diagnostic criteria for SCAP.

Exclusion Criteria:

* Confirmed diagnosis of hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP);

  * Expected death within 24 hours;

    * Presence of septic shock prior to randomization; ④ History of allergy or contraindications to corticosteroids (e.g., active gastrointestinal bleeding, severe osteoporosis, uncontrolled hyperglycemia, bone marrow suppression);

      * Active fungal (except Pneumocystis jirovecii), tuberculosis, or hepatitis infection;

        * Receiving ongoing corticosteroid therapy at a dose equivalent to prednisone \> 1 mg/kg/day due to underlying disease; ⑦ Participation in this trial within the past 90 days; ⑧ Refusal to sign informed consent.
```

## Arms

- **Standard of Care** (PLACEBO_COMPARATOR) — Receive Standard of care for SCAP, including antibiotics and respiratory support.
- **Low dose steroids** (EXPERIMENTAL) — Intervention: Receive 0.5mg/kg Methylprednisolone
- **Moderate dose steroids** (EXPERIMENTAL) — Intervention: Receive 1.0mg/kg Methylprednisolone

## Interventions

- **Low dose steroids** (DRUG) — Receive 0.5mg/kg Methylprednisolone
- **Moderate dose steroids** (DRUG) — Receive 1.0mg/kg Methylprednisolone
- **Saline (0.9% NaCl)** (DRUG) — Saline 100ml

## Primary Outcomes

- **28-day all cause mortality** _(time frame: 28 days from inclusion)_ — death at 28th day after inclusion

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07152587.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07152587*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*